STOCK TITAN
  1. Home
  2. Sec-filings
  3. ESPR
  4. [144] Esperion Therapeutics, Inc. SEC Filing

[144] Esperion Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ESPR logo
Esperion Therape

NASDAQ:ESPR

ESPR Rankings

#3231 Ranked by Market Cap
N/A Ranked by Dividends

ESPR Latest News

Oct 3, 2025
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 19, 2040
Sep 19, 2025
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
Aug 29, 2025
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Aug 26, 2025
Esperion to Participate in Upcoming September Investor Conferences
Aug 7, 2025
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPR Latest SEC Filings

Sep 17, 2025
[144] Esperion Therapeutics, Inc. SEC Filing
Sep 17, 2025
[144] Esperion Therapeutics, Inc. SEC Filing
Sep 17, 2025
[144] Esperion Therapeutics, Inc. SEC Filing
Sep 18, 2025
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity
Sep 18, 2025
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity

ESPR Stock Data

584.71M
200.57M
0.56%
50.62%
11.08%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
ANN ARBOR